A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor−Positive Breast Cancer

2023-506700-12-00 Protocol GO39932 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 18 Jun 2018 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 7 sites · Protocol GO39932

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 158
Countries 1
Sites 7

Locally Advanced or Metastatic Estrogen Receptor−Positive Breast Cancer

Key facts

Sponsor
Genentech Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
18 Jun 2018 → ongoing
Decision date (initial)
2024-02-23
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-506700-12-00
EudraCT number
2017-002083-41

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Locally Advanced or Metastatic Estrogen Receptor−Positive Breast Cancer

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Genentech Inc.

Sponsor organisation
Genentech Inc.
Address
1 Dna Way
City
South San Francisco
Postcode
94080-4918
Country
United States

Scientific contact point

Organisation
Genentech Inc.
Contact name
US Program Manager Product Development Regulatory

Public contact point

Organisation
Genentech Inc.
Contact name
US Program Manager Product Development Regulatory

Locations

1 EU/EEA country · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruitment ended 45 7
Rest of world
Korea, Republic of, United Kingdom, Australia, United States
113

Investigational sites

Spain

7 sites · Ongoing, recruitment ended
MD Anderson Cancer Center
Oncologia, Calle De Arturo Soria Nº 270, 28033, Madrid
Hospital Universitario Hm Sanchinarro
Oncologia Medica, Calle Ona 10, 28050, Madrid
Hospital Universitari Vall D Hebron
Oncologia Medica, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona
Institut Catala D'oncologia
Oncologia Medica, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
Hospital Clinico Universitario De Valencia
Oncologia Medica, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital General Universitario Gregorio Maranon
Oncologia Medica, Calle Del Doctor Esquerdo 46, 28007, Madrid
Hospital Universitario Ramon Y Cajal
Oncologia Medica, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2018-06-18 2018-07-06 2021-01-14

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-21 Spain Acceptable
2024-02-23
2024-02-23
2 SUBSTANTIAL MODIFICATION SM-1 2024-06-15 Spain Acceptable
2024-07-30
2024-07-30
3 SUBSTANTIAL MODIFICATION SM-3 2025-01-31 Spain Acceptable
2025-04-07
2025-04-07
4 SUBSTANTIAL MODIFICATION SM-4 2025-06-27 Spain Acceptable
2025-09-03
2025-09-05
5 NON SUBSTANTIAL MODIFICATION NSM-1 2026-04-21 Spain Acceptable
2025-09-03
2026-04-21